Business
Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines
SAN CARLOS, Calif., May 20, 2026--Engage Biologics Inc. ("Engage"), a preclinical biotechnology company pioneering non-viral DNA delivery, today announced that it has been acquired by Eli Lilly and Company ("Lilly").
About this update from Eli Lilly And Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3750,"height":667,"url":"https://media.zenfs.com/en/business-wire.com/ff3f3769a2dce946ee0bd6d95b35bdb9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0Q0AL0eUd2d.wd25Eo9F_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3MQ--/https://media.zenfs.com/en/business-wire.com/ff3f3769a2dce946ee0bd6d95b35bdb9","width":960,"height":171},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/0IziUSBcvV8ml7GGwk9s8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTExNA--/https://media.zenfs.com/en/business-wire.com/ff3f3769a2dce946ee0bd6d95b35bdb9","width":640,"height":114},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/MDdb3_UMT4BSUxdObqj6Cg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MjY-/https://media.zenfs.com/en/business-wire.com/ff3f3769a2dce946ee0bd6d95b35bdb9","width":1200,"height":213}},"lazy":false},{"type":"text","content":"Engage Bio’s Tethosome platform is designed to improve the potency, tolerability, and redosability of non-viral DNA","length":115,"tagName":"p"},{"type":"text","content":"Acquisition combines Engage’s innovative platform with Lilly’s broad genetic medicines capabilities and portfolio","length":113,"tagName":"p"},{"type":"text","content":"SAN CARLOS, Calif., May 20, 2026--(BUSINESS WIRE)--Engage Biologics Inc. ("Engage"), a preclinical biotechnology company pioneering non-viral DNA delivery, today announced that it has been acquired by Eli Lilly and Company ("Lilly").","length":253,"tagName":"p"},{"type":"text","content":"Engage is developing the Tethosome platform, a novel non-viral DNA delivery system designed to overcome key limitations in DNA delivery, including potency, tolerability, and redosability. The platform combines engineered DNA payloads with lipid nanoparticle delivery and an mRNA-encoded proprietary Tethosome technology designed to enhance localization and increase expression. Engage’s DNA payloads are further engineered to improve tolerability while retaining key advantages of DNA-based therapies, including durability and programmability","length":542,"tagName":"p"},{"type":"text","content":""With a lean organization and modest seed funding, I am incredibly proud of the rapid progress Engage has made toward a new class of genetic medicines. This is a testame...